What is the 13F Pro Quality Score for XLO?

13F Pro ranks Xilio Therapeutics, Inc. (XLO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XLO's current score at https://13fpro.ai/research/XLO (free sign-up required for the full ranking).

Where does 13F Pro source XLO data?

All Xilio Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Xilio Therapeutics, Inc. files with the SEC under CIK 1840233. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XLO in?

Xilio Therapeutics, Inc. (XLO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XLO research updated on 13F Pro?

XLO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xilio Therapeutics, Inc.(XLO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1840233 XLO stock profile & AI dashboard →

13F Pro Quality Score

26.9/100

Rank #2,489 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

6.6/100

Balance Sheet

6.1/100

Earnings Quality

30.0/100

Free Cash Flow

8.3/100

Institutional Flow

0.6/100

Revenue Scale

9.9/100

Dilution Risk

11.7/100

XLO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xilio Therapeutics, Inc. (XLO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XLO at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,489 of 2,879 stocks — the bottom half of the AI-ranked universe. XLO scores in the top quartile across revenue growth (99.1). Areas of concern include institutional flow (0.6) and balance sheet strength (6.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Xilio Therapeutics, Inc. reports quarterly revenue of $12.6M, net income of $-9.5M, free cash flow of $-22.9M. Top institutional holders of XLO by reported 13-F value include Bain Capital Life Sciences Investors,, GILEAD SCIENCES,, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. XLO trades on the Nasdaq exchange and files with the SEC under CIK 1840233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xilio Therapeutics, Inc. directly from SEC EDGAR. Xilio Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 27 and 31 since 2026, currently 26.9 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Xilio Therapeutics, Inc.

Quirks, history, and lore behind XLO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on oncology.
2
The Numbers
A micro-cap with no approved products and no commercial revenue — the balance sheet is essentially cash runway funding its pipeline.
3
The History
Founded in the 2010s and went public in 2021, riding a wave of investor enthusiasm for next-generation immuno-oncology startups.
4
The Secret
Its whole thesis is that systemic immunotherapies are too blunt — it engineers drugs designed to activate only inside the tumor microenvironment, sparing healthy tissue.
5
The Lore
The company's name is a mashup evoking tumor-localized biology — its lead programs are conditionally activated cytokine and checkpoint therapies that stay silent until they reach the right zip code.
6
The Giveaway
Its ticker spells out almost exactly what it is: a biotech whose name starts with an X, ends in "-lio," and whose whole mission is keeping cancer-killing immune signals locked until they hit the tumor itself.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$12.6M

Net Income

Q1 2026

$-9.5M

Free Cash Flow

Q1 2026

$-22.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+589.9% YoY

$43.8MFY 2025

FY22 —FY23 —FY24 $6.3MFY25 $43.8M

Net Income

+39.8% YoY

$-35.0MFY 2025

FY22 $-88.2MFY23 $-76.4MFY24 $-58.2MFY25 $-35.0M

Operating Income

+30.7% YoY

$-42.0MFY 2025

FY22 $-89.1MFY23 $-79.1MFY24 $-60.6MFY25 $-42.0M

EPS (Diluted)

+72.5% YoY

$-4.19FY 2025

FY22 $-3.22FY23 $-2.78FY24 $-15.24FY25 $-4.19

Total Assets

+117.6% YoY

$154.7MFY 2025

FY22 $139.2MFY23 $60.9MFY24 $71.1MFY25 $154.7M

Op. Cash Flow

+72.8% YoY

$-5.0MFY 2025

FY22 $-75.7MFY23 $-68.6MFY24 $-18.4MFY25 $-5.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$43.8M +589.9%	$6.3M	—	—	—	—
Net Income	$-35.0M +39.8%	$-58.2M +23.8%	$-76.4M +13.4%	$-88.2M -16.4%	$-75.8M	—
Operating Income	$-42.0M +30.7%	$-60.6M +23.4%	$-79.1M +11.2%	$-89.1M -18.8%	$-75.0M	—
EPS (Diluted)	$-4.19 +72.5%	$-15.24 -448.2%	$-2.78 +13.7%	$-3.22 +76.2%	$-13.52	—
Total Assets	$154.7M +117.6%	$71.1M +16.7%	$60.9M -56.2%	$139.2M -36.2%	$218.1M	—
Operating Cash Flow	$-5.0M +72.8%	$-18.4M +73.2%	$-68.6M +9.4%	$-75.7M +6.2%	$-80.8M	—

AI Insight: XLO Financial Trends

Xilio swung to Q4 2025 profitability on $14M revenue, but equity volatility and negative operating cash flow persist into Q1 2026.

• Revenue grew 6.5× from Q2 2024 ($2M) to Q3 2025 ($19M), then moderated to $13–14M in recent quarters.

• Operating margin improved sharply: Q4 2025 showed –86% (–$12M op income on $14M revenue), best among recent periods.

• Net income turned positive in Q4 2025 (+$10M) after 9 consecutive loss quarters, but returned to –$10M loss in Q1 2026.

⚠ Operating cash flow negative for 5 of last 6 quarters (–$22M in Q1 2026); profitability gain appears non-cash-backed.

⚠ Equity swung from –$8M (Q3 2025) to +$73M (Q1 2026)—likely capital raise; sustainability of operations uncertain.

AI Insight: XLO Ratio Trends

Xilio swung to Q4 2025 profitability before reverting to heavy losses in Q1 2026, signaling volatility rather than sustained improvement.

• Q4 2025 showed anomalous profitability (NPM +75.7%, ROE +117.5%, ROA +26.8%), a sharp reversal from Q3 2025 losses, suggesting one-time events rather than operational momentum.

• Q1 2026 returned to significant losses across all metrics: OpMargin -111.6%, NPM -75.3%, ROA -23.3%, ROIC -77.8%, erasing Q4 gains.

• Operating margin deteriorated 101.5pp from Q3 2025 (-10.1%) to Q1 2026 (-111.6%), reflecting severe cost control collapse.

⚠ Q4 2025 profitability reversal unexplained by sequential data; investigate accounting treatment or asset sales driving anomaly.

⚠ TTM ROA of -19.1% and ROIC of -58.2% remain deeply negative; company burning capital at scale with no clear path to profitability.

Get alerted when XLO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xilio Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XLO

Bain Capital Life Sciences Investors, LLC
$5.6M664,021 sh
GILEAD SCIENCES, INC.
$5.5M650,389 sh
Frazier Life Sciences Management, L.P.
$3.6M422,505 sh
Sio Capital Management, LLC
$1.3M152,464 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.0M123,660 sh
Caligan Partners LP
$943.0K112,128 sh
Merck & Co., Inc.
$891.3K105,982 sh
Stonepine Capital Management, LLC
$539.6K64,162 sh
MORGAN STANLEY
$483.5K57,493 sh
RENAISSANCE TECHNOLOGIES LLC
$416.9K49,566 sh

Fund	Value	Shares
Bain Capital Life Sciences Investors, LLC	$5.6M	664,021
GILEAD SCIENCES, INC.	$5.5M	650,389
Frazier Life Sciences Management, L.P.	$3.6M	422,505
Sio Capital Management, LLC	$1.3M	152,464
VANGUARD CAPITAL MANAGEMENT LLC	$1.0M	123,660
Caligan Partners LP	$943.0K	112,128
Merck & Co., Inc.	$891.3K	105,982
Stonepine Capital Management, LLC	$539.6K	64,162
MORGAN STANLEY	$483.5K	57,493
RENAISSANCE TECHNOLOGIES LLC	$416.9K	49,566

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XLO on your watchlist

Track score changes the day Xilio Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XLO a good stock to buy?

13F Pro's AI-powered analysis of Xilio Therapeutics, Inc. (XLO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XLO are available on the XLO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XLO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XLO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xilio Therapeutics, Inc.'s investment landscape.